Sinobiopharma Announces SFDA Approval of Anti-Hypertension Drug Perindopril

NANTONG CITY, China, May 11 /PRNewswire-FirstCall/ -- Sinobiopharma, Inc. (OTC
Bulletin Board: SNBP) ("Sinobiopharma" or, the "Company") is pleased to
announce that it has received approval from the Chinese State Food and Drug
Administration (SFDA) to manufacture and market its formulation of
Perindopril, an anti-hypertension drug.

Perindopril, used alone or in combination with other medications to treat high
blood pressure, is the latest generation of a class of medications called
angiotensin-converting enzyme (ACE) inhibitors. It supports circulation by
preventing the production of chemicals that occur naturally in the body but
constrict blood vessels.

As the first Chinese producer of Perindopril, Sinobiopharma comes to market
with significant competitive advantages, including lower cost active
pharmaceutical ingredients (API), and being the first in the world to offer
capsule formulation, which is not only easier to swallow, but also has greater
efficacy and reduced side effects compared to earlier versions of the drug.
Prior to SFDA approval of Sinobiopharma's version, Servier (France) was the
only firm to market Perindopril in China. Perindopril completed clinical
trials in September 2007.

High blood pressure is a leading cause of stroke, heart attack and kidney
failure; it affects an estimated one billion people worldwide. In China, the
incidence of cardiovascular and cerebrovascular diseases is on the rise,
costing patients approximately RMB 300 billion (US $37 billion) in medical
expenses each year. Of this amount, some RMB 30 billion (US $3.7 billion) is
spent directly on the treatment of hypertension, according to China's Ministry
of Health.

High blood pressure affects nearly one in five Chinese adults during their
lifetime, according to the State Council of China.

"SFDA approval of Sinobiopharma's formulation of Perindopril strengthens our
product portfolio in keeping with our strategy of focusing on first-to-market
generic and innovative drugs," says Lequn Huang, Company President and CEO.

About Sinobiopharma
Sinobiopharma, Inc. is a fully integrated and highly innovative biotechnology
company engaged in the research and development, manufacture and marketing of
biopharmaceutical products in China, the world's fastest growing
pharmaceutical market. Known as Dong Ying (Jiangsu) Pharmaceutical Co. Ltd. in
China, the Company's current therapeutic focus is on anesthesia-assisted
agents and cardiovascular drugs.

Contacts:
Sinobiopharma, Inc.
Investor Relations
1-877-568-0188

FORWARD-LOOKING STATEMENTS
This news release may include "forward-looking statements" regarding
Sinobiopharma, Inc., and its subsidiaries, business and project plans. Such
forward-looking statements are within the meaning of Section 27A of the
Securities Act of 1933, as amended, and section 21E of the United States
Securities and Exchange Act of 1934, as amended, and are intended to be
covered by the safe harbor created by such sections. Where Sinobiopharma, Inc.
expresses or implies an expectation or belief as to future events or results,
such expectation or belief is believed to have a reasonable basis. However,
forward-looking statements are subject to risks, uncertainties and other
factors, which could cause actual results to differ materially from future
results expressed, projected or implied by such forward-looking statements.
Sinobiopharma, Inc. does not undertake any obligation to update any
forward-looking statement, except as required under applicable law.

SOURCE Sinobiopharma, Inc.

Investor Relations of Sinobiopharma, Inc., 1-877-568-0188